medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2008, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2008; 53 (3)

Side effects of intravenous ondansetron

Zamora LJ, Briones CG, Boone EAC, Díaz AMA, Quintero MA, Ortiz GA

Language: Spanish
References: 15
Page: 166-168
PDF size: 120.93 Kb.


ABSTRACT

Ondansetron is a selective 5-HT3 receptor antagonist used as an effective antiemetic in oncology and surgical patients, is believed to be safe and is associated with very few reported serious side effects. However, recently ondansetron has been associated with several cases of extrapyramidal side effects, anaphylactoid reactions, prolongation of the QTc interval, and acute myocardial ischemia. We describe a case of a severe perioperative reaction due to the administration of ondansetron intravenously used to prevent postoperative nausea and vomiting.


REFERENCES

  1. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain EMJ. Prolongation of QTc Interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102 (6): 1094-1100.

  2. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, Nikoloff M, Wu L, Andrews D. The impact of pharmacogenomics on postoperative nausea and vomiting. Anesthesiology 2005; 102 (3): 543-549.

  3. Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: A preliminary report. J Clin Anesth 2005; 17 (1): 62-65.

  4. Baguley WA, Hay WT, Mackie KP, Cheney FW, Cullen BF. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Anesth Analg 1997; 84: 1380-1381.

  5. Ross AK, Ferrero-Conover D. Anaphylactoid reaction due to the administration of ondansetron in a pediatric neurosurgical patient. Anesth Analg 1998; 87: 779-780. 

  6. Tramer MR et al. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87 (6): 1277-1289.

  7. Bosek V, Hu P, Robinson L. Acute myocardial ischemia after administration of ondansetron hydrochloride. Anesthesiology 2000; 92 (3): 885.

  8. Chen M, Tanner A, Gallo-Torres H. Anaphylactoid-anaphylactic reactions associated with ondansetron. Ann Intern Med 1993; 119: 862.

  9. Kossey JL, Kwok KK. Anaphylactoid reactions associated with ondansetron. Ann Pharmacother 1994; 28: 1029-1030.

  10. Frigerio C, Buchwalder PA, Spertini F. Ondansetron: Reasons to be restrictive. Lancet 1996; 347: 1484-1485.

  11. Framarino Dei Malatesta M, Veneziano M, Fiorelli C et al. Ondansetron in chemotherapy-induced emesis: Our experience. Eur J Gynaecol Oncol 1995; 16: 97–106.

  12. Bryson J. Clinical safety of ondansetron. Semin Oncol 1992; 19: 26–32.

  13. Smith R. Safety of ondansetron. Eur J Cancer Clin Oncol 1989; 25: S47–50.

  14. Stoelting R. Pharmacology and physiology in anesthesic practice. 3th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999. p. 406.

  15. Sprung J, Choudhry FM, Hall BA. Extrapyramidal reactions to ondansetron: Cross-reactivity between ondansetron and prochlorperazine? Anesth Analg 2003; 96: 1374-1376.




2020     |     www.medigraphic.com